Showing results (321-330 of 329) with videos related to

Sort By:
Pageof 33
You have reached the last page of results.This site can display upto 329 results.
Molecular Pharmaceutics|December 9, 2022
NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety MarginElke Lipka, Aaron M Chadderdon, Cheryl C Harteg, et al.
The Journal of Allergy and Clinical Immunology|September 16, 2015
Practice parameter for the diagnosis and management of primary immunodeficiencyFrancisco A Bonilla, David A Khan, Zuhair K Ballas, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Nature Medicine|December 8, 2020
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trialRaffael Nachbagauer, Jodi Feser, Abdollah Naficy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 10, 2015
Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013Daniel C Payne, Rangaraj Selvarangan, Parvin H Azimi, et al.
The Journal of Infectious Diseases|June 16, 2016
Rotavirus Strain Trends During the Postlicensure Vaccine Era: United States, 2008-2013Michael D Bowen, Slavica Mijatovic-Rustempasic, Mathew D Esona, et al.
The Lancet. Infectious Diseases|October 22, 2019
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trialDavid I Bernstein, Jeffrey Guptill, Abdollah Naficy, et al.
Plos One|July 23, 2011
Pathways activated during human asthma exacerbation as revealed by gene expression patterns in bloodUnnur S Bjornsdottir, Stephen T Holgate, Padmalatha S Reddy, et al.
Open Forum Infectious Diseases|March 4, 2015
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical TrialMark J Mulligan, David I Bernstein, Sharon Frey, et al.
Pageof 33